178 related articles for article (PubMed ID: 38221889)
21. SUMOylation Pattern Predicts Prognosis and Indicates Tumor Microenvironment Infiltration Characterization in Bladder Cancer.
Xia QD; Sun JX; Xun Y; Xiao J; Liu CQ; Xu JZ; An Y; Xu MY; Liu Z; Wang SG; Hu J
Front Immunol; 2022; 13():864156. PubMed ID: 35418978
[TBL] [Abstract][Full Text] [Related]
22. m
Zhang B; Wu Q; Li B; Wang D; Wang L; Zhou YL
Mol Cancer; 2020 Mar; 19(1):53. PubMed ID: 32164750
[TBL] [Abstract][Full Text] [Related]
23. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
Wang Z; Tu L; Chen M; Tong S
BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
[TBL] [Abstract][Full Text] [Related]
24. Immune landscape of distinct subtypes in urothelial carcinoma based on immune gene profile.
Peng M
Front Immunol; 2022; 13():970885. PubMed ID: 36003383
[TBL] [Abstract][Full Text] [Related]
25. Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs.
Liu D; Xu S; Chang T; Ma S; Wang K; Sun G; Chen S; Xu Y; Zhang H
Front Immunol; 2022; 13():916800. PubMed ID: 35860239
[TBL] [Abstract][Full Text] [Related]
26. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
Lyu X; Wang P; Qiao Q; Jiang Y
BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
[TBL] [Abstract][Full Text] [Related]
27. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
[No Abstract] [Full Text] [Related]
28. A combination of ssGSEA and mass cytometry identifies immune microenvironment in muscle-invasive bladder cancer.
Wang X; Pan L; Lu Q; Huang H; Feng C; Tao Y; Li Z; Hu J; Lai Z; Wang Q; Tang Z; Xie Y; Li T
J Clin Lab Anal; 2021 May; 35(5):e23754. PubMed ID: 33813769
[TBL] [Abstract][Full Text] [Related]
29. M6A Classification Combined With Tumor Microenvironment Immune Characteristics Analysis of Bladder Cancer.
Zhu H; Jia X; Wang Y; Song Z; Wang N; Yang Y; Shi X
Front Oncol; 2021; 11():714267. PubMed ID: 34604051
[TBL] [Abstract][Full Text] [Related]
30. Identification of m6A modification patterns and development of m6A-hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer.
Shen X; Zhong J; He J; Han J; Chen N
Front Immunol; 2022; 13():978092. PubMed ID: 36105819
[TBL] [Abstract][Full Text] [Related]
31. Tertiary lymphoid structure patterns aid in identification of tumor microenvironment infiltration and selection of therapeutic agents in bladder cancer.
An Y; Sun JX; Xu MY; Xu JZ; Ma SY; Liu CQ; Liu Z; Wang SG; Xia QD
Front Immunol; 2022; 13():1049884. PubMed ID: 36420257
[TBL] [Abstract][Full Text] [Related]
32. Tumor Microenvironment-Mediated Immune Profiles Characterized by Distinct Survival Outcome and Immunotherapeutic Efficacy in Breast Cancer.
Xu L; Hu Y; Liu W
Front Genet; 2022; 13():840348. PubMed ID: 35401704
[No Abstract] [Full Text] [Related]
33. The significance of m6A RNA methylation modification in prognosis and tumor microenvironment immune infiltration of cervical cancer.
Guo Y; Bai Y; Wang L; Xu Z; Wang X; Wang W
Medicine (Baltimore); 2022 Jul; 101(26):e29818. PubMed ID: 35777046
[TBL] [Abstract][Full Text] [Related]
34. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
35. Low expression and Hypermethylation of ATP2B1 in Intrahepatic Cholangiocarcinoma Correlated With Cold Tumor Microenvironment.
Zhang X; He Y; Ren P; Chen L; Han Z; Qi L; Chen L; Luo Y; Zhang N; Lu W; Guo H
Front Oncol; 2022; 12():927298. PubMed ID: 35875160
[TBL] [Abstract][Full Text] [Related]
36. Use of Novel m6A Regulator-mediated Methylation Modification Patterns in Distinct Tumor Microenvironment Profiles to Identify and Predict Glioma Prognosis and Progression, T-cell Dysfunction, and Clinical Response to ICI Immunotherapy.
Zhao B; Xiang Z; Wu B; Zhang X; Feng N; Wei Y; Zhang W
Curr Pharm Des; 2023; 29(1):60-78. PubMed ID: 36503445
[TBL] [Abstract][Full Text] [Related]
37. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
38. Computational recognition of lncRNA signature of tumor-infiltrating B lymphocytes with potential implications in prognosis and immunotherapy of bladder cancer.
Zhou M; Zhang Z; Bao S; Hou P; Yan C; Su J; Sun J
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32382761
[TBL] [Abstract][Full Text] [Related]
39. A Novel TGF-β Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer.
Liu Z; Qi T; Li X; Yao Y; Othmane B; Chen J; Zu X; Ou Z; Hu J
Front Immunol; 2021; 12():791924. PubMed ID: 34975891
[TBL] [Abstract][Full Text] [Related]
40. A novel cuproptosis pattern and tumor immune microenvironment characterization in urothelial carcinoma of the bladder.
Feng H; Deng Z; Huang Y; Liu Z; Ruan Y; Wang T; Liu J
Front Immunol; 2023; 14():1219209. PubMed ID: 37662947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
